Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

References

• Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–2857.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shan J, Smith T, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001;92:2501–2507.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian HM, O’Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632–2641.
   PubMed Web of Science ®Google Scholar
• Axdorph U, Stenke L, Grimfors G, et al. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase - a report from the Swedish CML Group. Br J Haematol. 2002;118:1048–1054.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–2541.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008;22:2176–2183.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–3553.
   PubMed Web of Science ®Google Scholar
• Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93:1792–1796.
   PubMed Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116:3852–3861.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530–3539.
   PubMed Web of Science ®Google Scholar
• Saussele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol. 2015;94:159–165.
   Web of Science ®Google Scholar
• Kroeger H, Jelinek J, Estécio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112:1366–1373.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113:1315–1325.
   PubMed Web of Science ®Google Scholar
• Kuang SQ, Tong WG, Yang H, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia. 2008;22:1529–1538.
   PubMed Web of Science ®Google Scholar
• Rush LJ, Raval A, Funchain P, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004;64:2424–2433.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Mohrbacher AF, Tsai YC, et al. Quantitative measure of c-abl andp15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000;95:2990–2992.
   PubMed Web of Science ®Google Scholar
• Jelinek J, Gharibyan V, Estecio MRH, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011;6:e22110.
   PubMed Web of Science ®Google Scholar
• Janssen JJ, Denkers F, Valk PJ, et al. Methylation patterns in CD34+ chronic myeloid leukemia blast crisis cells. Haematologica. 2010;95:1036–1037.
   PubMed Web of Science ®Google Scholar
• Uehara E. Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis. Oncology Letters 2012;3:190–192.
   PubMed Web of Science ®Google Scholar
• Heller G, Topakian T, Altenberger C, et al. Next-generation sequencing identifies major DNA methylation changes during progression of Ph +  chronic myeloid leukemia. Leukemia. 2016;30:1861–1868.
   PubMed Web of Science ®Google Scholar
• Ghez D, Micol J-B, Pasquier F, et al. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis. Eur J Cancer. 2013;49:3666–3670.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007;109:1543–1549.
   PubMed Web of Science ®Google Scholar
• Deau B, Nicolini FE, Guilhot J, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2011;35:777–782.
   PubMed Web of Science ®Google Scholar
• Söderlund S, Dahlén T, Sandin F, et al. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. Eur J Haematol. 2017;98:57–66.
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood. 2015;125:3230–3235.
   PubMed Web of Science ®Google Scholar
• Kantardjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phase of chronic myelogenous leukemia. Leukemia. 1997;11:1617–1620.
   PubMed Web of Science ®Google Scholar
• Abaza Y, Kantarjian HM, Borthakur G, et al. An open-label, phase I study of dasatinib in combination with decitabine in patients (Pts) with accelerated or blastic phase chronic myeloid leukemia (CML). Blood. 2015;126:1589.
   Web of Science ®Google Scholar
• Jiang LC, Luo JM. Role and mechanism of decitabine combine with tyrosine kinase inhibitors in advanced phase chronic myeloid leukemia. Oncol Lett. 2017;14:1295–1302.
   PubMed Web of Science ®Google Scholar